New Delhi: GVK Biosciences today said it has licensed its proprietary databases to the USFDA as part of a collaboration in drug repositioning to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases. Under the agreement, GVK Bio has licensed its SAR, PK and Toxicity Database (GOSTAR) to the US Food and Drug Administration (USFDA), the company said in a statement. "The material transfer agreement forms the basis of collaboration in drug repositioning, wherein the initial focus will be to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases," it added. Drug repositioning is the process of application of known drugs and compounds to new diseases.
Malaysia Airlines plane crashed off Vietnam coast
Yogendra Yadav`s face smeared with ink
Modi`s `chai pe charcha` on women empowerment!
Kingfisher women employees say shame on Vijay Mallya